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Abstract. 
 
 
Background and Purpose 
MRI-defined carotid plaque hemorrhage (MRIPH) can predict recurrent 
cerebrovascular ischemic events in severe symptomatic carotid stenosis. It is less 
clear whether MRIPH can improve risk stratification despite optimised medical 
secondary prevention in those with moderate risk.  
 
 
 
 
Methods 
151symptomatic patients with 30-99% carotid artery stenosis (median age:77, 60.5% 
men) clinically deemed to not benefit from endarterectomy were prospectively 
recruited to undergo MRI and clinical follow-up (mean: 22 months). The clinical 
Carotid Artery Risk (CAR) score could be evaluated in 88 patients. MRIPH+ve was 
defined as plaque intensity >150% that of adjacent muscle. Survival analyses were 
performed with recurrent infarction (stroke or diffusion positive cerebral ischemia) as 
the main endpoint.   
 
Results 
55 participants showed MRIPH+ve; 47 had low, 36 intermediate and 5 high CAR 
scores. Cox regression showed MRIPH as a strong predictor of future infarction 
(HR=5.2, 95%CI=1.64–16.34, P=0.005, corrected for degree of stenosis), also in the 
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subgroup with 50-69% stenosis (HR=4.1, 95%CI=1-16.8, P=0.049). The absolute risk 
of future infarction was 31.7% at 3 years in MRIPH+ve versus 1.8% in patients 
without (P<0.002). MRIPH increased cumulative risk difference of future infarction 
by 47.1% at 3 years in those with intermediate CAR score (P=0.004). 
 
Conclusions 
The study confirms MRIPH to be a powerful risk marker in symptomatic carotid 
stenosis with added value over current risk scores. For patients undergoing current 
secondary prevention medication with clinically uncertain benefit from recanalization 
i.e. those with moderate degree stenosis and intermediate CAR scores, MRIPH offers 
additional risk stratification.  
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Introduction  
Carotid endarterectomy (CEA) reduces the risk of stroke in symptomatic carotid 
disease of significant severity; however not all patients with symptomatic carotid 
stenosis benefit equally from CEA1. Recent guidelines recommend surgical 
intervention for stenosis of at least 50%2, 3 without specifying any restrictions to avoid 
unnecessary CEA in lower risk patients such as women with moderate degree stenosis 
and late presentation. The underpinning evidence from randomised controlled trial 
more than two decades ago has however been put in question due to improved 
outcomes attributed to current secondary prevention medical treatment4. In current 
practice, there is hence uncertainty when considering CEA in addition to current 
optimised medical therapy resulting in practice variation especially in the moderate 
risk group.  It is conceivable but unknown whether and to which degree early and 
optimal initiation of medical therapy may have reduced the benefit and cost-
effectiveness of CEA for patients with low-intermediate risk. To address these 
concerns, a randomized controlled trial is underway (www.ecst2.com) for patients 
with low to intermediate stroke risk based on a modified European Carotid Surgery 
Trial risk model to take modern medical management into account.  However, clinical 
risk models have limitations5 and there is potential for significant improvement 
afforded by modern imaging techniques such as MRI of the plaque to discriminate 
high-risk carotid plaque features previously identified by histology6. The presence of 
MRIPH has previously been shown to predict recurrent ipsilateral ischemic events 
and stroke in patients with symptomatic carotid artery stenosis7-10. With an estimated 
0.6% annualized risk of recurrent stroke where MRIPH was absent vs. 23% in 
MRIPH+ve7, MRIPH holds great promise for risk-based stratification of carotid 
endarterectomy. Current data is however insufficient to confirm whether MRIPH 
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predicts future cerebral infarction in patients with low-intermediate risk on current 
medical therapy.   
 
This prospective study assessed whether MRIPH could be used reliably to stratify the 
future risk in symptomatic patients with carotid artery stenosis considered unsuitable 
for CEA and receiving optimal medical treatment alone due to perceived low benefit-
risk ratio or patient preference. We also compared risk prediction by MRIPH and the 
CAR score.  
 
Methods 
Description of study sample 
The Imaging in Carotid Artery Disease (ICAD) study was a single-center 
observational study between November 2010 and February 2015.  None of the data 
presented here had been previously published, while the interrelation between brain 
imaging and cognitive status of the cohort are published elsewhere (Meng et al, 
Hosseini et al., submitted). Patients were consecutively recruited from the Fast-track 
TIA clinic and stroke wards at Nottingham University Hospitals NHS Trust. All the 
patients had been reviewed by Stroke Physicians and received optimised medical 
therapy for secondary stroke prevention according to current guidelines. 
Ultrasonographic data from vascular clinic were screened to determine eligibility for 
recruitment.  A few participants were identified and referred from adjacent hospitals 
in Derby and Mansfield (Figure I-supp).  Inclusion criteria were; >18 years old adults 
with recent anterior circulation transient ischemic attack (TIA, defined as sudden 
focal neurological deficits lasting less than 24 hours), amaurosis fugax (AmF: 
painless transient monocular visual loss) or ischemic stroke (sudden focal 
 6 
neurological deficits lasting at least 24 hours), as confirmed by a Stroke Physician, in 
the previous 6 months and an ipsilateral carotid stenosis of 30-99%, life expectancy of 
>3 years, and competency to consent. MRI contraindications, and planned ipsilateral 
CEA were exclusion criteria. All participants provided written informed consent as 
approved by the local Ethics Committee, and Research and Development 
Departments at all three participant-identifying centers.   
 
 
Imaging Protocol 
As part of clinical care, all participants had carotid ultrasonography prior to 
recruitment. The degree of carotid stenosis was assessed according to ultrasound 
criteria adapted from the NASCET trial11 as used in CAVATAS12. Contrast-MR or 
CT angiography was used when carotid ultrasound was unable to determine the 
degree of stenosis. 
 
At recruitment, participants were assessed for cardiovascular risk factors and had 
brain and carotid MRI at Nottingham University Hospital, performed on a 3T Achieva 
(Philips; version 3.1.2 software). For carotid wall imaging, a single coronal T1-
weighted 3-dimensional gradient echo sequence was performed using blood nulling 
and a water excitation pulse that excludes signal from fat. The sequence parameters 
were as follows:  TR 8.8ms, TE 4.1ms, FA 10°, TI 570ms, FOV 346×346 mm, matrix 
384×180, slice thickness 0.9 mm, number of slices 102. The acquisition took 
approximately five minutes. The coded anonymous images were reformatted to axial 
images (1mm slice thickness, 150 slices) and transferred to a locally held secure 
server.   
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Quantitative analysis of the MR images was then performed using JAVA imaging 
(JIM) software (www.xinapse.com), by two trained researchers (AAH, RJS) and 
adjudicated by an experienced neuroradiologist (DPA).  Although the presence of 
carotid plaque hemorrhage (MRIPH+ve) is easily visible in most cases (Figure 1), the 
presence of MRIPH in this study was diagnosed quantitatively according to 
previously validated criteria13, 14. Whilst blinded to the clinical data, areas of high 
signal were identified within the carotid artery wall within 1cm from the bifurcation.  
The slice with subjectively the highest signal intensity was chosen and the 
hyperintense area selected. A signal intensity ratio (SIR) was calculated by comparing 
the mean intensities of the carotid artery compared with that of adjacent 
sternocleidomastoid muscle (SIR=SIplaque/SImuscle). The presence of MRIPH was 
diagnosed if the normalized SIR between the two was at least 1.5 (MRIPH+ve).  
 
 
 
Clinical Assessment, Carotid Artery Risk score and Follow-up 
Clinical assessments for any cerebrovascular ischemic event, vascular risk factors, co-
morbidities and medications were recorded at recruitment and follow-up reviews.  
CAR scores were defined based on degree of carotid stenosis using NASCET criteria, 
time since last event, primary symptomatic event, diabetes, myocardial infarction, 
age, sex, peripheral vascular disease, treated hypertension, and ulcerated plaque 
surface (www.ECST2.com). 
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Participants were followed up at every 6-month interval until the end of study (range 
132-1587 days, median 710 days) or terminating points i.e. death or ipsilateral CEA 
(range: 3-1333 days, median 461 days). A Stroke or Neurology Physician verified 
recurrent ischemic events, and ipsilateral stroke was defined as neurological deficits 
ipsilateral to the indexed carotid stenosis lasting at least 24 hours. The primary 
endpoint ‘ipsilateral recurrent cerebral infarction’ was defined as stroke (CT or MRI 
confirmed) or TIA with evidence of diffusion change on brain MRI corresponding to 
the index clinical deficit (DWI+ve TIA). Secondary endpoints were stroke alone and 
any ipsilateral cerebrovascular event, i.e. stroke, TIA or AmF. Further censoring 
endpoints were ipsilateral CEA, death or withdrawal of consent.  In addition, new 
atrial fibrillation at the time of recurrent event, contralateral or bi-hemispheric stroke, 
and myocardial infarction were noted during the follow-up period.  
 
 
 
 
 
 
 
Statistical Analysis  
 
 
To assess the independent effects of MRIPH and degree of carotid stenosis, we aimed 
to record at least 20 new ipsilateral events over the entire study period to empower 
bivariate regression analysis for MRIPH and degree of stenosis.   
 
Kaplan-Meier (KM) survival analysis and log rank tests were used to assess the 
associations between MRIPH and the rate of new ipsilateral clinically manifest 
cerebral infarctions (primary endpoint: stroke and DWI+ve TIA), as well as MRIPH 
and all ipsilateral cerebrovascular events (secondary endpoints: stroke, TIA and 
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AmF). Cerebrovascular ischemic event rates per 100 person-years were calculated for 
each outcome.  KM analysis was also performed to examine the CAR score 
associations with the rates of primary and secondary endpoints.  
 
Time to ipsilateral infarction or any cerebrovascular ischemic event was analyzed for 
MRIPH using a bivariate Cox proportional hazard model adjusted for degree of 
carotid artery stenosis (subgroups of ≥50% and <50% stenosis). Univariate Cox 
models for MRIPH were calculated for the subgroups of moderate (50-69%), and 
mild (30-49%) degree of stenosis. Similarly, time to event was tested for CAR scores 
using univariate and bivariate Cox model including MRIPH. SPSS Statistics was 
used; P<0.05 was considered significant. 
 
Results 
A total of 152 subjects fulfilled all inclusion and exclusion criteria (Figure I-supp). 60 
(39.5%) were women with median age of 79±12 years (men: 76±12 years; P=0.42). 
Fifty-five participants (36.2%) were identified to have MRIPH ipsilateral to the 
indexed ischemic event and 97 did not have ipsilateral MRIPH (MRIPH-ve)(Table 1).  
In line with previous findings7, 13, MRIPH was again more likely to be present in men 
(χ²=9.05, P=0.003). 
 
During the follow-up period (range 3-1587 days), 20 ipsilateral events occurred 
including 15 primary endpoints (14 strokes, 1 DWI+ve TIA), as well as 3 TIAs, 2 
AmF. The recurrent strokes were classified as large artery atherosclerotic in 11, 
lacunar stroke in three (of which 1 was bilateral), and cardioembolic in two. One 
patient was lost to follow-up and therefore excluded from the survival analysis.  22 
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participants died during the follow-up (mean 602±353 days), and there were 9 
ipsilateral CEAs, following a reconsideration of surgical intervention by the clinical 
team. Further events included 1 contralateral stroke, 1 contralateral TIA and 1 
bilateral stroke, which were excluded from the survival analysis as per study protocol.  
 
 
MRIPH predicts future ipsilateral ischemic events in patients managed by medical 
treatment 
Univariate Cox-regression analysis confirmed that MRIPH was significantly 
associated with future ipsilateral clinically manifest infarction (stroke or DWI+ve 
TIA, HR=5.1, 95%CI=1.6–16, P=0.005). When controlled for ≥50% or <50% 
stenosis, the HR was 5.2 (95%CI=1.64-16.34, P=0.005) (Figure 2-A). Similarly, 
MRIPH significantly predicted future stroke alone (univariate Cox analysis; HR=5.1, 
95%CI=1.6–15.9, P=0.006 and bivariate Cox analysis adjusted for carotid stenosis; 
HR=5.12, 95%CI=1.63–16.3, P=0.005)(Figure 2-B) and all recurrent ipsilateral 
ischemic events (univariate Cox analysis; HR=3.6, 95%CI=1.4–9.1, P=0.006 and 
bivariate Cox analysis adjusted for carotid stenosis; HR=3.7, 95%CI=1.5–9.2, 
P=0.006) (Figure II-supp).  
A small group of patients (n=17) with severe stenosis were included as they were 
clinically felt to be unfit for surgery or were unwilling to consent to surgery. Hence, 
we repeated the analysis for the participants with less than 70% stenosis, which 
yielded similar results. 
 
Using Kaplan Meier risk estimate, the absolute risk difference between those with and 
without MRIPH for recurrent infarct (stroke or DWI+ve TIA) was +12.8% at year 1 
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and +29.9% at year 3 (Table 2). The absolute risk of infarction in the MRIPH+ve group 
was 12.8% by one year, compared with a negligible risk for the MRIPH-ve group.  The 
absolute risk with presence of MRIPH was 31.7% by 3 years, compared with that of 
1.8% for the MRIPH-ve. This equates to the presence of MRIPH resulting in an 
estimated 13/100 extra infarctions at 1 year and an extra 29/100 at 3 years, compared 
to MRIPH-ve subjects. In our study population of patients with 30-99% carotid artery 
stenosis not undergoing CEA, the number needed to harm (NNH) for those with 
MRIPH was about 8 by 1 year, NNH=5 by 2 years and NNH=4 by 3 years compared 
with MRIPH-ve. The risk difference beyond 3 years did not increase; three strokes 
occurred after 3 years in the MRIPH-ve subgroup, of which two were likely cardio-
embolic secondary to atrial fibrillation or a mechanical heart valve based on 
bihemispheric evidence of infarct and clinical risk assessment. 
 
MRIPH predicts stroke in moderate degree stenosis 
A total of 72 participants with 50-69% stenosis suffered 11 recurrent ischemic events 
(Table 3) including 9 strokes. In this subgroup, MRIPH was significantly associated 
with future ipsilateral infarctions/strokes (HR=4.1, 95%CI=1.0–16.8, P=0.049). No 
recurrent DWI+ve TIA was seen during the follow up in this subgroup.  For the 
secondary endpoint of all recurrent ischemic events, we found no significant 
association with MRIPH (HR=2.56, 95%CI=0.77–8.6, P=0.128(Figure 2-C,D). 
In the subgroup with low degree stenosis (30-49%), the imaging marker was not 
significantly associated with recurrence (HR=4.3, 95%CI=0.45–41.8, P=0.2), but this 
subgroup analysis was underpowered with only 6 events. 
Using Kaplan Meier risk estimates for the moderate degree stenosis subgroup, the risk 
difference between those with and without MRIPH for future stroke or DWI+ve TIA 
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was +20% and +35.3% at years 1 and 3, respectively. The annualized risk of recurrent 
stroke or DWI+ve TIA in this group in the presence of MRIPH was 14.3%, compared 
with 3.2% in the MRIPH-ve subgroup. 
The NNH in this group was 5 by 1 year, and 3 by 2 and 3 years. This means that 
approximately 1 in 5 patients with MRIPH in moderate degree stenosis group risked 
recurrent ipsilateral infarction by 1 year, while no ipsilateral infarct occurred in the 
subgroup without MRIPH. In moderate degree stenosis, 1 in 3 patients had future 
infarcts by 3 years whilst no infarct occurred in the MRIPH-ve group over the first 3 
years.  
 
MRIPH and the carotid artery risk (CAR) score 
Of 89 participants with >50% carotid stenosis, one patient had uncertain date of indexed 
event and was hence excluded from CAR scores evaluation (Table 1). Mean and 
categorical CAR scores were significantly higher in MRIPH+ve group compared with 
MIRPH-ve (P=0.001 and P=0.005, respectively).  
In our cohort, no recurrent ischemic event occurred in the subgroup with high CAR 
scores but the respective subgroup was very small (n=5) due to our inclusion criteria. 
14 patients in the subgroup with low or intermediate CAR scores (n=83) experienced 
recurrent ipsilateral ischemic events (11 stroke, 1 TIA, 2 AmF) during the follow up 
(mean: 657; ranged 3-1491 days).  
KM survival analysis for predictive value of CAR scores was insignificant (P=0.22). 
Bivariate regression analysis demonstrated no significant effect of CAR (P=0.49), but 
confirmed significant independent association of MRIPH with future cerebral 
infarction (HR=6.7, 95%CI=1.7-26, P=0.006).  Patients with intermediate CAR 
scores and MRIPH+ve (n=36) risked future stroke (no DWI+ve TIA event was 
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observed) at a higher rate than expected; i.e. 29.5% by 1 year and 47.1% by 3 years, 
but no stroke or DWI+ve TIA was observed in patients with MRIPH-ve by 3 years 
(P=0.004).  
 
Discussion 
In patients with symptomatic carotid artery disease managed with current medical 
treatment alone, MRI-defined plaque hemorrhage significantly predicted future 
ipsilateral cerebral infarction and stroke alone.  Importantly, MRIPH also predicted 
recurrence in clinical subgroups with lower or uncertain benefit from carotid 
endarterectomy.  
 
In symptomatic moderate degree (50-69%) stenosis, carotid MRIPH carried an 
estimated ipsilateral stroke risk difference of +35% at 3 years, compared to those 
without MRIPH despite optimised medical treatment.  In this group, MRIPH allowed 
to identify those with >15% annual risk of stroke or cerebral infarction per 100-
persons year. In contrast, absence of MRIPH identified the subgroup with minimal 
risk of stroke in the first year. It is worth noting that the observed risk difference 
between MRIPH+ve and MRIPH-ve patients outweighs the risk of carotid 
endarterectomy in specialised centers (between 2.6 to 4.5%15), thus highlighting the 
potential benefit of targeted surgery.  
 
MRIPH was associated with significantly higher CAR risk, but its association with 
future clinical events was independent of CAR. Moreover, in our cohort, CAR scores 
did not predict cerebrovascular ischemic events. In contrast, MRIPH allowed to risk 
stratify patients with intermediate CAR scores showing that in the presence of 
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MRIPH nearly half will risk stroke by 3 years. This is in line with our previous 
findings in severe carotid stenosis for which the similar ECST score also failed to 
show predictive power16.  
 
Clinical risk scores such as ECST/CAR are extremely helpful, quick to apply and 
inexpensive, but less specific to the thromboembolic risk than MRIPH17. ECST/CAR 
are necessarily based on historic actuarial data rather than the individual risk and they 
are not reflective of evolution in medical treatment. Nevertheless, the CAR score 
adjusts for the expected risk reduction due to improved medical therapy. Also, plaque 
ulceration on ultrasonography that is part of ECST/CAR may not be as reliably 
detected compared with historic conventional angiography (NASCET11). In the 
future, it will be desirable to develop a modified enhanced CAR score accounting for 
the evidenced power of MRIPH to index the risk of future events furthering a 
precision medicine approach in secondary stroke prevention care.  
 
In a previous meta-analysis, we found that carotid MRIPH significantly increased the 
risk of recurrent ischemic events several fold (OR=12.2, 95% CI=5.5-27.1) in patients 
with 30-99% symptomatic carotid stenosis7, 18. Much of the included data for 
moderate degree stenosis8, 18-20 was however limited due to heterogeneity in degree of 
stenosis, duration of follow up, mixed with asymptomatic carotid disease, and 
reflective of the past clinical practice8, 9, 18, 19, 21, 22. Our new observational study 
overcomes these issues and provides evidence that the current risk models and risk 
management can be improved for patients with expected low-moderate risk.  
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The presented results are from a single-center limiting their generalizability into local 
standard practice. Nevertheless, multiple studies across diverse populations, scanner 
platforms and protocols, have consistently shown that carotid plaque hemorrhage is 
associated with future or recurrent cerebrovascular ischemic events in symptomatic 
carotid artery stenosis7, 18, 23. We believe that there is now sufficient evidence to 
justify refinement of clinical risk assessment scores with individualized data using 
MRIPH. Whether the proven added value of MRIPH for risk prediction will translate 
into predictive value of risk-benefit from CEA or carotid stenting remains to be 
demonstrated in the ongoing (ECST-2, MRI substudy), and future randomized control 
trials using MRIPH defined risk stratification. 
 
 
Summary 
MRIPH is a significant predictor of future cerebral infarction and stroke in patients 
with symptomatic carotid artery stenosis. MRIPH status affords clinically useful risk 
stratification in those with moderate carotid stenosis or intermediate CAR scores. 
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Table 1- Demographic characteristics and risk factors in participants with and without PH on ipsilateral carotid MRI (at 
recruitment): 
 MRIPH+  (n=55) MRIPH- (n=97) P Value 
Age, median years (interquartile range) 76 (13) 77 (11) 0.28 
Sex-female, n (%) 13 (23.6) 47 (48.5) 0.003* 
Diabetes mellitus, n (%) 10 (18.2) 23 (23.7) 0.43 
Hypertension, n (%) 45 (81.8) 78 (80.4) 0.83 
Ischemic heart disease, n (%) 14 (25.5) 27 (27.8) 0.75 
Atrial fibrillation 12 (21.8) 21 (21.6) 0.98 
Statin use prior to indexed ischemic event†, n (%) 33 (60.0) 45 (46.4) 0.11 
Use of statin after indexed ischemic event 55 (100) 92 (94.8) ††  
Smoking habit, n (%)    
               Smokers 12 (21.8) 26 (26.8) 0.05 
               Non-smokers 11 (20.0) 34 (35.1)  
               Ex-smokers‡ 32 (58.2) 37 (38.1)  
Antiplatelet/anticoagulant agent(s) used prior to indexed ischemic event, n (%)   0.36 
               Aspirin   14 (25.5) 19 (19.6)  
               Clopidogrel 17 (30.9) 36 (37.1)  
               Dual (Aspirin and [Dipyridamole or Clopidogrel]) 11 (20.0) 9 (9.3)  
               Warfarin 4 (7.3) 7 (7.2)  
               None 9 (16.4) 26 (26.8)  
Use of antiplatelet or anticoagulation after indexed ischemic event 55 (100) 96 (100) †††  
Degree of Stenosis §, n (%)   0.62 
               30-49% 22 (40.0) 41 (42.3)  
               50-69% 25 (45.5) 47 (48.5)  
               70-99% 8 (14.5) 9 (9.3)  
Type of symptom on presentation, n(%)   0.073 
               Stroke 35 (63.6) 41 (42.3)  
               TIA 15 (27.3) 42 (43.3)  
               Amaurosis fugax 3 (5.5) 11 (11.3)  
               Retinal stroke 2 (3.6) 3 (3.1)  
CAR score, total number of participants  (mean scores) 33 (9.7)  55 (7.1) 0.001* 
             Low CAR scores, i.e. 0-7.5% risk, number 12 35  
             Intermediate CAR scores i.e. 7.5-15% risk, number 17 19  
             High CAR scores i.e. >15% risk, number 4 1  
Time between presenting symptom and MRI, median days (interquartile range) 23 (33) 26 (33)  
Total number of carotid endarterectomy, n (%) 4 (7.3) 5 (5.2)  
Follow-up until any endpoint point**, median days (interquartile range) 552 (665) 674.5 (610.25)  
TIA: Transient Ischemic Attack; MRIPH+: presence of hyperintense signal on MRI; MRIPH-: Absence of hyperintense signal on 
MRI. 
*Significantly different (<0.05) between MRIPH+ and MRIPH- groups. †Patients were on regular statin therapy more than 6 
months prior to inclusion onto the study. ††All patients were given statin immediately after the ischemic event, but 5 patients 
stopped taking statin due to intolerance during the follow-up. †††All patients were given antiplatelet or anticoagulation according 
to the guidelines, but one patient stopped taking antiplatelet within a few weeks due to personal preference and against medical 
advice. ‡Ex-smokers were defined as stopped smoking for more than 6 months.  §Based on Ultrasound criteria described in the 
methods. **Follow-up period from the entry point until the end of study period, ipsilateral carotid endarterectomy or death if did 
not meet the primary endpoint (recurrent event). 
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Table 2- Risk Estimation for recurrent ipsilateral stroke or TIA with evidence of restricted diffusion on MRI (DWI+ TIA) in 
patients with symptomatic carotid artery stenosis and presence of MRIPH (MRIPH+) 
 Cumulative Risk 
(KM- Estimate*), 
1 Year, % 
Cumulative Risk 
(KM- Estimate*), 
3 Year, % 
Risk Difference 
(vs. MRIPH- 
group), 1 year, % 
Risk Difference 
(vs. MRIPH- 
group), 3 year, % 
Number of 
events/person
-years 
Event rate per 
100 person-
years 
50-60% stenosis and MRIPH+  20% 35.3% +20 +35.3 6/38.9 15.4 
50-69% stenosis and MRIPH- 0  0   3/92.4 3.2 
30-99% stenosis and MRIPH+ 12.8% 31.1% +12.8 +29.3 11/97.1 11.3 
30-99% stenosis and MRIPH- 0 1.8%   4/184.3 2.2 
*Kaplan-Meier Estimate 
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Table 3- Recurrent events during the follow-up period. 
 Total Ips. 
Ischemic Events 
Ips. stroke or 
DWI+ TIA 
Ips. large artery 
atherosclerotic 
stroke* 
Ips. lacunar 
stroke* 
Ips. cardioembolic 
stroke* 
Contralateral 
Ischemic Event  
50-69% stenosis and MRIPH+  6  6 6 0 0 0 
50-69% stenosis and MRIPH- 5 (1 DWI-ve TIA, 
1 AmF) 
3  1 1 1 2 (1 stroke, 1 
TIA) 
30-99% stenosis and MRIPH+ 13 (1 DWI-ve 
TIA, 1 AmF)  
11 (10 stroke) 11 0 0 0 
30-99% stenosis and MRIPH- 7 (2 DWI-ve TIA, 
1 AmF) 
4 stroke 1 2 1 2 
*according to TOAST criteria. TIA: Transient Ischemic Attack; DWI+ve TIA: TIA with evidence of restricted diffusion on MRI 
brain; DWI-ve TIA: TIA with no evidence of restricted diffusion on MRI brain; AmF: Amaurosis fugax; MRIPH+ve: presence of 
hyperintense signal on MRI; MRIPH-ve: Absence of hyperintense signal on MRI. 
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Figure 1- Axial views of T1-weighted MRI to detect plaque hemorrhage. 
Hyperintense signals (b-d, white arrows) show carotid plaque hemorrhage on 3T MRI 
scanner; black arrows (a) show absence of plaque hemorrhage; asterisks indicate the 
lumen of internal carotid artery. 
a) No signal hyperintensity, MRIPH-ve; b) Large moderately MRIPH+ve; c) Small 
strongly hyperintense MRIPH+ve; d) Large strongly hyperintense MRIPH+ve.  
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Figure 2-A,Kaplan-Meier plot showing stroke or DWI+ TIA survival analysis for all 
study participants (30-99% stenosis) by presence or absence of MRIPH (χ²=9.64, 
P=0.002). B, KM plot representing recurrent stroke for all study participants by 
presence or absence of MRIPH (χ²=9.49, P=0.002). C, KM plot showing stroke or 
DWI+ TIA survival analysis for participants with 50-69% ipsilateral carotid stenosis 
by presence or absence of MRIPH  (χ²=4.51, P=0.034). D, KM plot showing recurrent 
ipsilateral survival analysis for participants with 50-69% ipsilateral carotid stenosis by 
presence or absence of MRIPH  (χ²=2.5, P=0.114). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
